Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE013 (USA) (Dr. Clarke)
· consented 2023-02-09
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
severe
serious
assessed
2026-08-18
Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-16 (study day 122); relationship: N; serious criteria: life-threatening
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-25 (study day 131); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 188); relationship: N
moderate
assessed
2026-08-18
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 191); relationship: N
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-15 (study day 213); relationship: N
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.